Welcome to our dedicated page for Tilray Brands news (Ticker: TLRY), a resource for investors and traders seeking the latest updates and insights on Tilray Brands stock.
Tilray Brands, Inc. (NASDAQ: TLRY) is a pioneering company in the field of medical and recreational cannabis production and research. Headquartered in Canada, Tilray has positioned itself as a global leader with a commitment to providing safe, consistent, and reliable therapy to patients and consumers worldwide. The company operates in multiple regions, including Canada, the United States, Europe, Australia, and Latin America, serving a diverse clientele ranging from patients and physicians to pharmacies, hospitals, and governments.
In 2021, Tilray underwent a significant transformation when legacy Aphria acquired legacy Tilray through a reverse merger, consolidating their strengths under the name Tilray Brands, Inc. This strategic merger expanded Tilray's market reach and product portfolio, bolstering its position in both the medical cannabis export market and the recreational cannabis sector.
Tilray's core offerings include a comprehensive range of cannabis products, from medical cannabis treatments to CBD products and alcoholic beverages. One of its latest ventures is the Ridge Runner West Coast IPA, a craft beer that has gained popularity for its complex flavors and craftsmanship. Additionally, Tilray's subsidiary, Widmer Brothers Brewing, recently launched a new Hefe Variety 12 Pack, showcasing innovative wheat beer styles.
The company is also making strides in the cannabis beverage market with the introduction of XMG Zero and XMG+ beverages. These products offer a variety of THC and CBG ratios, bringing unique flavors and high-quality ingredients to consumers across Canada.
Tilray's commitment to innovation extends beyond beverages. Solei, one of its wellness brands, has introduced the Warming Deep Tissue Stick, a cannabis-infused topical solution designed for active lifestyle enthusiasts. Meanwhile, Good Supply has released the Twisted All-in-One rechargeable vape, offering a potent and flavorful vaping experience.
Overall, Tilray Brands, Inc. continues to lead the way in cannabis research, cultivation, and distribution, with a diversified portfolio that caters to the needs of a global community. The company remains dedicated to enhancing the lives of its consumers through high-quality, innovative products that inspire well-being.
Tilray, Inc. (NASDAQ: TLRY) announced a bylaw amendment reducing the quorum requirement for shareholder meetings from a majority to one-third of voting power. This change is in connection with the proposed merger with Aphria Inc., allowing for shareholder votes at the upcoming special meeting on April 30. Tilray encourages all stockholders to participate in voting, regardless of share numbers. Proxies already submitted will be counted unless revoked. Tilray operates globally in cannabis research, cultivation, and distribution, serving thousands of customers across 17 countries.
Tilray (NASDAQ: TLRY) announced the adjournment of its special stockholder meeting, originally set for April 16, 2021, to April 30, 2021, to allow more time for stockholders to vote on the business combination with Aphria Inc. Stockholders who have already voted do not need to recast their votes. The meeting will be held via live webcast, and all stockholders are urged to participate. The transaction aims to strengthen Tilray’s market position in the cannabis industry and enhance shareholder value.
Aphria and Tilray are set to hold special meetings on April 14 and April 16, 2021, to approve their proposed business combination. Aphria has received necessary regulatory approvals and an interim order from the Ontario Superior Court for the arrangement. The combined entity will become the world's largest cannabis company, projecting pro forma revenue of US$685 million. Both Boards recommend their shareholders vote ‘FOR’ the transaction. Expected cost synergies of US$78 million will enhance operational efficiency, while the combined company aims for growth in domestic and international markets.
Tilray (NASDAQ: TLRY) has received approvals from New Zealand's Ministry of Health to launch its medical cannabis products nationwide. As a leading provider in Australia and New Zealand, Tilray aims to offer high-quality medical cannabis products, starting with its Purified CBD line. By Q2 2021, the company plans to expand its GMP-certified product range. Tilray collaborates with prominent research institutions to explore cannabis treatments for various health conditions. This expansion enhances patient access to medical cannabis in New Zealand.
Tilray, a global cannabis leader (Nasdaq: TLRY), announced its fiscal year 2020 and Q4 results, reporting a total revenue of $56.6 million, up 20.5% YoY, with cannabis revenue rising 46% to $41.2 million. The company achieved a net loss of $(3.0) million, significantly improved from $(219.8) million in Q4 2019. Adjusted EBITDA reached $2.2 million, marking a turnaround. Anticipating $100 million in synergies from its merger with Aphria, Tilray aims for enhanced market positioning. Cash reserves totaled $189.7 million, setting a solid foundation for future growth opportunities.
Tilray Inc. (TLRY), a leader in cannabis, will release its 2020 fiscal year and Q4 results on February 17, 2021, after market close. A conference call is scheduled for 5:00 p.m. ET, accessible via a U.S. toll-free number 877-407-0792, or internationally at 201-689-8263. The call will also be available through a live webcast on the Tilray website, which will later be archived for viewing.
Tilray Inc. (NASDAQ: TLRY) has partnered with Grow Pharma to import and distribute medical cannabis products in the UK. This agreement facilitates access for UK patients to GMP-certified medical cannabis solutions. Tilray plans to offer a range of products by March 2021, available through private practices or the NHS. According to CEO Brendan Kennedy, this partnership is a significant step in improving patient access in the UK, while Managing Director Sascha Mielcarek emphasizes the company's commitment to becoming a leading supplier as demand increases.
Tilray, a global leader in cannabis, announced its first export of GMP-certified medical cannabis from Portugal to Spain, in collaboration with Worldpharma Biotech. This shipment, approved by Spain's AEMPS, will support clinical trials for conditions such as Alzheimer's and Parkinson's. Tilray's pharmaceuticals-grade product is designed to meet stringent EU standards, enhancing patient access to reliable cannabis treatments. This milestone marks the 17th country receiving Tilray cannabis, showcasing its commitment to global medical cannabis standards.
FAQ
What is the current stock price of Tilray Brands (TLRY)?
What is the market cap of Tilray Brands (TLRY)?
What does Tilray Brands, Inc. do?
Where is Tilray Brands, Inc. headquartered?
What was the significance of the 2021 merger?
What are some of Tilray's wellness products?
What recent product has Tilray introduced in the beverage market?
What is the Ridge Runner West Coast IPA?
What vaping product has Good Supply recently launched?
What markets does Tilray operate in?
What is the mission of Tilray Brands, Inc.?
How does Tilray ensure the quality of its products?
